Bone turnover markers in osteoporosis: a common statement on their use of the Society for Metabolic Bone Diseases within the Czech Medical Association of J.E. Purkyne (SMBD CzMA JEP) and the Czech Society of Clinical Biochemistry within the Czech Medical Association of J.E. Purkyne (CSCB CzMA JEP)

Czech version

Authors: Pikner Richard ^1,2,3; Palička Vladimír ⁴; Rosa Jan ⁵; Zikán Vít ⁶; Švagera Zdeněk ⁷; Racek Jaroslav ²; Friedecký Bedřich ^8,4; Kratochvíla Josef ⁸; Zima Tomáš ⁹
Authors‘ workplace: Oddělení klinických laboratoří, pracoviště kostního metabolizmu, Klatovská nemocnice a. s., Klatovy ¹; Ústav klinické biochemie a hematologie LF UK a FN Plzeň ²; Katedra záchranářství, diagnostických oborů a veřejného zdravotnictví, Fakulta zdravotnických studií Západočeské univerzity v Plzni ³; Ústav klinické biochemie a diagnostiky LF UK a FN Hradec Králové ⁴; Osteocentrum, Affidea Praha s. r. o., Praha ⁵; Ambulance pro metabolická onemocnění skeletu a poruchy kalciového metabolismu, III. interní klinika 1. LF UK a VFN v Praze ⁶; Ústav laboratorní diagnostiky, oddělení klinické biochemie FN Ostrava ⁷; SEKK spol. s r. o., Pardubice ⁸; Ústav lékařské biochemie a laboratorní diagnostiky 1. LF UK a VFN v Praze ⁹
Published in: Clinical Osteology 2020; 25(2): 65-82
Category:

Overview

The publication is a joint position of the Czech Society of Clinical Biochemistry and the Society for Metabolic Skeletal Diseases on the use of bone turnover markers in patients with osteoporosis. It is recommended to use PINP (Procollagen type I N-terminal propeptide) in μg/L as a marker of bone formation and CTX-I (C-terminal telopeptide of type I collagen) in ng/L as a marker of bone resorption. Blood sampling should be performed after an overnight fasting, an enormous physical load 24 hours prior to collection should be also avoided. Always take blood samples between hours 7:00 and 10:00 in the morning. Both serum and EDTA-plasma are acceptable. EDTA-plasma is preferable when CTX-I cannot be processed within 8 hours. PINP is not an optimal parameter in patients monitoring treated by corticoids, except anabolic therapy monitoring. Harmonised reference limits were recommended to unify their interpretation. For Roche systems we suggested basal reference range (CTX-I 100–600 ng/L for women, 70–700 ng/L for men; PINP 20–70 µg/L for both men and women), upper pathological limit (CTX-I 1 000 ng/L for women, 850 ng/L for men; PINP 100 µg/L for both men and women) For IDS systems we suggested to use basal reference limit (CTX-I 50–670 ng/L in women, 90–780 ng/L in men; PINP 20–75 µg/L in women, 20–80 µg/L in men), upper pathological limit (CTX-I 1 050 ng/L in women, 850 ng/L in men; PINP 100 µg/L in both men and women). For therapy monitoring a 25% change in serum CTX-I and PINP values is defined as LSC (least significant change), or in absolute values it means 100 ng/L change of serum CTX-I and 10 µg/L change for PINP.

Keywords:

bone markers – clinical use – CTX-I –osteoporosis – PINP – recommendation

Sources

Kanis JA, Cooper C, Rizzoli R et al. European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int 2019; 30(1): 3–44. Dostupné z DOI: <https://doi.org/10.1007/s00198–018–4704–5>.

Svedbom A, Hernlund E, Ivergård M et al. Osteoporosis in the European Union: a compendium of country-specific reports. Arch Osteoporos 2013; 8(1–2): 137. Dostupné z DOI: <https://doi.org/10.1007/s11657–013–0137–0>.

Stepan JJ, Vaculik J, Pavelka K et al. Hip Fracture Incidence from 1981 to 2009 in the Czech Republic as a Basis of the Country-Specific FRAX Model. Calcif Tissue Int 2012; 90(5): 365–372. Dostupné z DOI: <https://doi.org/10.1007/s00223–012–9582–9>.

Morris HA, Eastell R, Jorgensen NR et al. Clinical usefulness of bone turnover marker concentrations in osteoporosis. Clin Chim Acta 2017; 467: 34–41. Dostupné z DOI: <https://doi.org/10.1016/j.cca.2016.06.036>.

Eastell R, Pigott T, Gossiel F et al. Diagnosis of Endocrine Disease: Bone turnover markers: are they clinically useful? Eur J Endocrinol 2018; 178(1): R19–R31. Dostupné z DOI: <https://doi.org/10.1530/EJE-17–0585>.

Langdahl B, Ferrari S, Dempster DW. Bone modeling and remodeling: potential as therapeutic targets for the treatment of osteoporosis. Ther Adv Musculoskelet Dis 2016; 8(6): 225–235. Dostupné z DOI: Dostupné z DOI: <https://doi.org/10.1177/1759720X16670154>.

Sims NA, Martin TJ. Coupling the activities of bone formation and resorption: a multitude of signals within the basic multicellular unit. Bonekey Rep 2014; 3: 481. Dostupné z DOI: <https://doi.org/10.1038/bonekey.2013.215>.

Manolagas SC. Birth and death of bone cells: basic regulatory mechanisms and implications for the pathogenesis and treatment of osteoporosis. Endocr Rev 2000; 21(2):115–137. Dostupné z DOI: <https://doi.org/10.1210/edrv.21.2.0395>.

Vasikaran S, Eastell R, Bruyère O et al. Markers of bone turnover for the prediction of fracture risk and monitoring of osteoporosis treatment: a need for international reference standards. Osteoporos Int 2011; 22(2): 391–420. Dostupné z DOI: <https://doi.org/10.1007/s00198–010–1501–1>.

Bauer D, Krege J, Lane N et al. National Bone Health Alliance Bone Turnover Marker Project: current practices and the need for US harmonization, standardization, and common reference ranges. Osteoporos Int 2012; 23(10): 2425–2433. Dostupné z DOI: <https://doi.org/10.1007/s00198–012–2049-z>.

Szulc P. Bone turnover: Biology and assessment tools. Best Pract Res Clin Endocrinol Metab 2018; 32(5): 725–738. Dostupné z DOI: <https://doi.org/10.1016/j.beem.2018.05.003>.

Eastell R, Szulc P. Use of bone turnover markers in postmenopausal osteoporosis. Lancet Diabetes Endocrinol 2017; 5(11): 908–923. Dostupné z DOI: <https://doi.org/10.1016/S2213–8587(17)30184–5>.

Szulc P, Naylor K, Hoyle NR et al. Use of CTX-I and PINP as bone turnover markers: National Bone Health Alliance recommendations to standardize sample handling and patient preparation to reduce pre-analytical variability. Osteoporos Int 2017; 28(9): 2541–2556. Dostupné z DOI: <https://doi.org/10.1007/s00198–017–4082–4>.

Naylor K, Eastell R. Bone turnover markers: use in osteoporosis. Nat Rev Rheumatol 2012; 8(7): 379–89. Dostupné z DOI: <http://dx.doi.org/10.1038/nrrheum.2012.86>.

Cavalier E, Lukas P, Carlisi A et al. Aminoterminal propeptide of type I procollagen (PINP) in chronic kidney disease patients: the assay matters. Clin Chim Acta 2013; 425: 117–118. Dostupné z DOI: <https://doi.org/10.1016/j.cca.2013.07.016>.

Moser SC. Osteocalcin – A Versatile Bone-Derived Hormone. Front Endocrinol (Lausanne) 2019; 9: 6. Dostupné z DOI: <http://dx.doi.org/10.3389/fendo.2018.00794>.

Boskey AL, Gadaleta S, Gundberg C et al. Fourier transform infrared microspectroscopic analysis of bones of osteocalcin-deficient mice provides insight into the function of osteocalcin. Bone 1998; 23(3): 187–196. Dostupné z DOI: <https://doi.org/10.1016/S8756–3282(98)00092–1>.

Liu Y, Liu X, R Lewis J et al. Relationship between serum osteocalcin/undercarboxylated osteocalcin and type 2 diabetes: a systematic review/meta-analysis study protocol. BMJ Open 2019; 9(3): e023918. Dostupné z DOI: <https://doi.org/10.1136/bmjopen-2018–023918>.

Wei J, Karsenty G. An overview of the metabolic functions of osteocalcin. Rev Endocr Metab Disord 2015; 16(2): 93–98. Dostupné z DOI: <https://doi.org/10.1007/s11154–014–9307–7>.

Siller AF, Whyte MP. Alkaline Phosphatase: Discovery and Naming of Our Favorite Enzyme. J Bone Miner Res 2018; 33(2): 362–364. Dostupné z DOI: <https://doi.org/10.1002/jbmr.3225>.

Sharma U, Pal D, Prasad R. Alkaline Phosphatase: An Overview. Indian J Clin Biochem 2014; 29(3): 269–278. Dostupné z DOI: <https://doi.org/10.1007/s12291–013–0408-y>.

Szabo SM, Tomazos IC, Petryk A et al. Frequency and age at occurrence of clinical manifestations of disease in patients with hypophosphatasia: a systematic literature review. Orphanet J Rare Dis 2019; 14(1): 85. Dostupné z DOI: <https://doi.org/10.1186/s13023–019–1062–0>.

Tan A, Goodman K, Walker A et al. Long‐Term Randomized Trial of Intensive Versus Symptomatic Management in Paget’s Disease of Bone: The PRISM‐EZ Study. J Bone Miner Res 2017; 32(6): 1165–1173. Dostupné z DOI: <http://dx.doi.org/10.1002/jbmr.3066>.

Ketteler M, Block GA, Evenepoel P et al. Executive summary of the 2017 KDIGO Chronic Kidney Disease–Mineral and Bone Disorder (CKD-MBD) Guideline Update: what’s changed and why it matters. Kidney Int 2017; 92(6): 26–36. Dostupné z DOI: <https://doi.org/10.1016/j.kint.2017.04.006>.

Garnero P, Ferreras M, Karsdal MA et al. The Type I Collagen Fragments ICTP and CTX Reveal Distinct Enzymatic Pathways of Bone Collagen Degradation. J Bone Miner Res 2003; 18(5): 859–867. Dostupné z DOI: <https://doi.org/10.1359/jbmr.2003.18.5.859>.

Terpos E, Sezer O, Roodman D et al. The use of biochemical markers of bone remodeling in multiple myeloma: a report of the International Myeloma Working Group. Leukemia 2010; 24(10): 1700–1712. Dostupné z DOI: <https://doi.org/10.1038/leu.2010.173>.

Voorzanger-Rousselot N, Juillet F, Mareau E et al. Association of 12 serum biochemical markers of angiogenesis, tumour invasion and bone turnover with bone metastases from breast cancer: a crossectional and longitudinal evaluation. Br J Cancer 2006; 95(4):506–514. Dostupné z DOI: <https://doi.org/10.1038/sj.bjc.6603285>.

Halleen JM, Tiitinen SL, Ylipahkala H et al.Tartrate-resistant acid phosphatase 5b (TRACP 5b) as a marker of bone resorption. Clin Lab 2006; 52(9–10): 499–509.

Wheater G, Elshahaly M, Tuck SP et al. The clinical utility of bone marker measurements in osteoporosis. J Transl Med 2013; 11:201. Dostupné z DOI: <https://doi.org/10.1186/1479–5876–11–201>.

Haima P. Tartrate-Resistant Acid Phosphatase active isoform 5b. A biomarker for osteoclastic bone-resorption activity in renal insufficiency and cancer. Dostupné z WWW: <http://www.life-force-health.com/cms/wp-content/afbeeldingen/2015/02/TECO_TRAP5b_GB_0113_B.pdf>.[30–12–2019].

Shidara K, Inaba M, Okuno S et al. Serum Levels of TRAP5b, a New Bone Resorption Marker Unaffected by Renal Dysfunction, as a Useful Marker of Cortical Bone Loss in Hemodialysis Patients. Calcif Tissue Int 2008; 82(4): 278–287. Dostupné z DOI: <https://doi.org/10.1007/s00223–008–9127–4>.

Tang C, Liu Y, Qin H et al. Clinical significance of serum BAP, TRACP 5b and ICTP as bone metabolic markers for bone metastasis screening in lung cancer patients. Clin Chim Acta 2013; 426: 102–107. Dostupné z DOI: <https://doi.org/10.1016/j.cca.2013.09.011>.

D’Oronzo S, Brown J, Coleman R. The role of biomarkers in the management of bone-homing malignancies. J Bone Oncol 2017; 9: 1–9. Dostupné z DOI: <https://doi.org/10.1016/j.jbo.2017.09.001>.

Park SG, Jeong SU, Lee JH et al. The Changes of CTX, DPD, Osteocalcin, and Bone Mineral Density During the Postmenopausal Period. Ann Rehabil Med 2018; 42(3):441–448. Dostupné z DOI: <https://doi.org/10.5535/arm.2018.42.3.441>.

Lombardi G, Lanteri P, Colombini A, Banfi G. Blood biochemical markers of bone turnover: pre-analytical and technical aspects of sample collection and handling. Clin Chem Lab Med 2012; 50(5): 771–789. Dostupné z DOI: <https://doi.org/10.1515/cclm-2011–0614>.

Ingle BM, Hay SM, Bottjer HM et al. Changes in Bone Mass and Bone Turnover Following Distal Forearm Fracture. Osteoporos Int 1999; 10(5): 399–407. Dostupné z DOI: <https://doi.org/10.1007/s001980050246>.

Delanaye P, Souberbielle J-C, Lafage-Proust M-H et al. Can we use circulating biomarkers to monitor bone turnover in CKD haemodialysis patients? Hypotheses and facts. Nephrol Dial Transplant 2014; 29(5): 997–1004. Dostupné z DOI: <https://doi.org/10.1093/ndt/gft275>.

Eastell R, Garnero P, Audebert C et al. Reference intervals of bone turnover markers in healthy premenopausal women: Results from a cross-sectional European study. Bone 2012; 50(5): 1141–1147. Dostupné z DOI: <https://doi.org/10.1016/j.bone.2012.02.003>.

Chubb P, Byrnes E, Manning L, et al (2015) Reference intervals for bone turnover markers and their association with incident hip fractures in older men : the Health in Men Study. J Clin Endocrinol Metab 2015; 100(1): 90–99. Dostupné z DOI: <https://doi.org/10.1210/jc.2014–2646>.

Mchelsen J, Wallaschofski H, Friedrich N, et al. Reference intervals for serum concentrations of three bone turnover markers for men and women. Bone 2013; 57(2): 399–404. Dostupné z DOI: https://doi.org/10.1016/j.bone.2013.09.010

Guañabens N, Filella X, Monegal A et al. Reference intervals for bone turnover markers in Spanish premenopausal women. Clin Chem Lab Med 2016; 54(2): 293–303. Dostupné z DOI: <https://doi.org/10.1515/cclm-2015–0162>.

Huang Y, Eapen E, Steele S et al. Establishment of reference intervals for bone markers in children and adolescents. Clin Biochem 2011: 44(10–11): 771–778. Dostupné z DOI: <https://doi.org/10.1016/j.clinbiochem.2011.04.008>.

Bayer M. Reference values of osteocalcin and procollagen type I N-propeptide plasma levels in a healthy Central European population aged 0–18 years. Osteoporos Int 2014; 25(2): 729–736. Dostupné z DOI: <https://doi.org/10.1007/s00198–013–2485–4>.

Herrmann D, Lauria F, Mårild S et al. Reference values of bone stiffness index and C-terminal telopeptide in healthy European children. Int J Obes 2014; 38(Suppl 2): S76–S85. Dostupné z DOI: <https://doi.org/10.1038/ijo.2014.138>.

Rauchenzauner M, Schmid A, Heinz-Erian P et al. Sex- and Age-Specific Reference Curves for Serum Markers of Bone Turnover in Healthy Children from 2 Months to 18 Years. J Clin Endocrinol Metab 2007; 92(2): 443–449. Dostupné z DOI: <https://doi.org/10.1210/jc.2006–1706>.

de Papp AE, Bone HG, Caulfield MP et al. A cross-sectional study of bone turnover markers in healthy premenopausal women. Bone 2007; 40(5): 1222–1230. Dostupné z DOI: <https://doi.org/10.1016/j.bone.2007.01.008>.

Glover SJ, Gall M, Schoenborn‐Kellenberger O et al. Establishing a Reference Interval for Bone Turnover Markers in 637 Healthy, Young, Premenopausal Women From the United Kingdom, France, Belgium, and the United States. J Bone Miner Res 2009; 24(3): 389–397. Dostupné z DOI: <https://doi.org/10.1359/jbmr.080703>.

Vasikaran SD, Chubb SP, Ebeling PR et al. Harmonised Australian Reference Intervals for Serum PINP and CTX in Adults. Clin Biochem Rev 2014; 35(4): 237–242.

Martínez J, Olmos JM, Hernández JL et al. Bone turnover markers in Spanish postmenopausal women. Clin Chim Acta 2009; 409(1–2): 70–74. Dostupné z DOI: <https://doi.org/10.1016/j.cca.2009.08.020>.

Morovat A, Catchpole A, Meurisse A et al. IDS iSYS automated intact procollagen-1-Nterminus pro-peptide assay: method evaluation and reference intervals in adults and children. Clin Chem Lab Med 2013; 51(10): 2009–2018. Dostupné z DOI: <https://doi.org/10.1515/cclm-2012–0531>.

Elecsys total P1NP, metodický list. Dostupné z WWW <https://dialog1.roche.com/cz/cs/eLabDoc ,downloaded 2018>.

Kostní markery, nepostradatelný nástroj v diferenciální diagnostice metabolických poruch kostí. Promo Material Osteo_v17.indd 8 Roche,17.09.2017.

Elecsys β-CrossLaps_serum, metodický list. Dostupné z WWW <https://dialog1.roche.com/cz/cs/eLabDoc, downloaded 2018>.

Olmos JM, Hernández JL, Martínez J et al. Bone turnover markers in Spanish adult men. Clin Chim Acta 2010; 411(19–20): 1511–1515. Dostupné z DOI: <https://doi.org/10.1016/j.cca.2010.06.010>.

Bauer DC, Black DM, Bouxsein ML et al. Treatment-Related Changes in Bone Turnover and Fracture Risk Reduction in Clinical Trials of Anti-Resorptive Drugs: A Meta-Regression. J Bone Miner Res 2018; 33(4): 634–642. Dostupné z DOI: <https://doi.org/10.1002/jbmr.3355>.

Assessment of fracture risk and its application to screening for postmenopausal osteoporosis : report of a WHO study group [meeting held in Rome from 22 to 25 June 1992]. WHO Technical Report 843:1994. ISBN 9241208430. Dostupné z WWW: <https://apps.who.int/iris/bitstream/handle/10665/39142/WHO_TRS_843_eng.pdf?sequence=1&isAllowed=y>.

[WHO Scientific Group]. Prevention and management of osteoporosis : report of a WHO scientific group 2000. World Health Organization: 2003. WHO Technical Report 921: Geneva 2003. ISBN 9241209216. Dostupné z WWW: https://apps.who.int/iris/bitstream/handle/10665/42841/WHO_TRS_921.pdf?sequence=1&isAllowed=y

Sornay‐Rendu E, Munoz F, Garnero P et al. Identification of Osteopenic Women at High Risk of Fracture: The OFELY Study. J Bone Miner Res 2005; 20(10):1813–1819. Dostupné z DOI: <https://doi.org/10.1359/JBMR.050609>.

Kanis JA et al. [WHO Scientific Group]. Assessment of osteoporosis at the primary health care level. WHO Scientific Group Technical Report 2007. Dostupné z WWW: <https://www.iofbonehealth.org/sites/default/files/WHO_Technical_Report-2007.pdf>.

Kanis JA, Johansson H, Cooper C et al. European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int 2013; 24(1): 23–57. Dostupné z DOI: <https://doi.org/10.1007/s00198–012–2074-y>.

Cosman F, de Beur SJ, LeBoff MS et al. Clinician’s Guide to Prevention and Treatment of Osteoporosis. Osteoporos Int 2014; 25(10): 2359–2381. Dostupné z DOI: <https://doi.org/10.1007/s00198–014–2794–2>.

Burch J, Rice S, Yang H et al. Systematic review of the use of bone turnover markers for monitoring the response to osteoporosis treatment: the secondary prevention of fractures, and primary prevention of fractures in high-risk groups. Health Technol Assess 2014; 18(11): 1–180. Dostupné z DOI: <https://doi.org/10.3310/hta18110>.

Luchavova M, Zikan V, Michalska D et al. The effect of timing of teriparatide treatment on the circadian rhythm of bone turnover in postmenopausal osteoporosis. Eur J Endocrinol 2011; 164(4):643–648. Dostupné z DOI: <https://doi.org/10.1530/EJE-10–1108>.

Glendenning P, Chubb SAP, Vasikaran S. Clinical utility of bone turnover markers in the management of common metabolic bone diseases in adults. Clin Chim Acta 2018; 481: 161–170. Dostupné z DOI: <https://doi.org/10.1016/j.cca.2018.03.009>.

Garnero P, Sornay-Rendu E, Chapuy M-C et al. Increased bone turnover in late postmenopausal women is a major determinant of osteoporosis. J Bone Miner Res 1996; 11(3): 337–349. Dostupné z DOI: <https://doi.org/10.1002/jbmr.5650110307>.

Rosen CJ, Chesnut CH, Mallinak NJ. The Predictive Value of Biochemical Markers of Bone Turnover for Bone Mineral Density in Early Postmenopausal Women Treated with Hormone Replacement or Calcium Supplementation. J Clin Endocrinol Metab 1997; 82(6): 1904–1910. Dostupné z DOI: <https://doi.org/10.1210/jcem.82.6.4004>.

Shieh A, Ishii S, Greendale GA et al. Urinary N-telopeptide and Rate of Bone Loss Over the Menopause Transition and Early Postmenopause. J Bone Miner Res 2016; 31(11): 2057–2064. Dostupné z DOI: <https://doi.org/10.1002/jbmr.2889>.

Rogers A, Hannon RA, Eastell R. Biochemical Markers as Predictors of Rates of Bone Loss After Menopause. J Bone Miner Res 2000; 15(7): 1398–1404. Dostupné z DOI: <https://doi.org/10.1359/jbmr.2000.15.7.1398>.

Brown JP, Prince RL, Deal C et al. Comparison of the Effect of Denosumab and Alendronate on BMD and Biochemical Markers of Bone Turnover in Postmenopausal Women With Low Bone Mass: A Randomized, Blinded, Phase 3 Trial. J Bone Miner Res 2009; 24(1): 153–161. Dostupné z DOI: <https://doi.org/10.1359/jbmr.0809010>.

Eastell R, Vrijens B, Cahall DL et al. Bone turnover markers and bone mineral density response with risedronate therapy: Relationship with fracture risk and patient adherence. J Bone Miner Res 2011; 26(7): 1662–1669. Dostupné z DOI: <https://doi.org/10.1002/jbmr.342>.

Johansson H, Odén A, Kanis JA et al. A Meta-Analysis of Reference Markers of Bone Turnover for Prediction of Fracture. Calcif Tissue Int 2014; 94(5):560–567. Dostupné z DOI: <https://doi.org/10.1007/s00223–014–9842-y>.

Cummings SR, Ferrari S, Eastell R et al. Vertebral Fractures After Discontinuation of Denosumab: A Post Hoc Analysis of the Randomized Placebo-Controlled FREEDOM Trial and Its Extension. J Bone Miner Res 2018; 33(2): 190–198. Dostupné z DOI: <https://doi.org/10.1002/jbmr.3337>.

Adler RA, Fuleihan GE-H, Bauer DC et al. Managing Osteoporosis in Patients on Long-Term Bisphosphonate Treatment: Report of a Task Force of the American Society for Bone and Mineral Research. J Bone Miner Res 2016; 31: 16–35. Dostupné z DOI: <https://doi.org/10.1002/jbmr.2708>.

Naylor KE, Bradburn M, Paggiosi MA et al. Effects of discontinuing oral bisphosphonate treatments for postmenopausal osteoporosis on bone turnover markers and bone density. Osteoporos Int 2018; 29(6): 1407–1417. Dostupné z DOI: <https://doi.org/10.1007/s00198–018–4460–6>.

Naylor KE, McCloskey EV, Jacques RM et al. Clinical utility of bone turnover markers in monitoring the withdrawal of treatment with oral bisphosphonates in postmenopausal osteoporosis. Osteoporos Int J 2019; 30(4):917–922. Dostupné z DOI: <https://doi.org/10.1007/s00198–018–04823–5>.

Reid IR, Black DM, Eastell R et al. Reduction in the Risk of Clinical Fractures After a Single Dose of Zoledronic Acid 5 Milligrams. J Clin Endocrinol Metab 2013; 98(2):557–563. Dostupné z DOI: <https://doi.org/10.1210/jc.2012–2868>.

Grey A, Bolland MJ, Horne A, et al.Five years of anti-resorptive activity after a single dose of zoledronate — Results from a randomized double-blind placebo-controlled trial. Bone 2012: 50(6): 1389–1393. Dostupné z DOI: <https://doi.org/10.1016/j.bone.2012.03.016>.

Kim TY, Bauer DC, McNabb BL et al. Comparison of BMD Changes and Bone Formation Marker Levels 3 Years After Bisphosphonate Discontinuation: FLEX and HORIZON‐PFT Extension I Trials. J Bone Miner Res 2019; 34(5): 810–816. Dostupné z DOI: <https://doi.org/10.1002/jbmr.3654>.

Boonen S, Ferrari S, Miller PD et al. Postmenopausal osteoporosis treatment with antiresorptives: Effects of discontinuation or long-term continuation on bone turnover and fracture risk—a perspective. J Bone Miner Res 2012; 27(5): 963–974. Dostupné z DOI: <https://doi.org/10.1002/jbmr.1570>. Erratum in J Bone Miner Res 2012; 27(11): 2414–2415. J Bone Miner Res 2012; 27(11): 2416.

Labels

Clinical biochemistry Paediatric gynaecology Paediatric radiology Paediatric rheumatology Endocrinology Gynaecology and obstetrics Internal medicine Orthopaedics General practitioner for adults Radiodiagnostics Rehabilitation Rheumatology Traumatology Osteology

Životní jubileum pana profesora MUDr. Jana Štěpána, DrSc.

Definition of osteoporotic (fragility) fracture: a statement of the Society for Metabolic Bone Diseases within the Czech Medical Association of J.E. Purkyne (SMOS CzMa of JEP)

Osteoporosis on systemic mastocytosis: case report

Treatment of atypical femoral fracture with teriparatide: case report

Osteolytic deposits of the pelvis leading to the diagnosis of primary hyperparathyreosis: case report

Article was published in

Clinical Osteology

2020 Issue 2